Torrent Pharma Q2 Profit Falls Nearly 10% as R&D Spending Rises
Torrent Pharmaceuticals reported a near 10% decline in second-quarter profit as higher research and development spending outweighed robust domestic demand for chronic therapies.
Indian drugmaker Torrent Pharmaceuticals (NSE:TORNTPHARM) said Friday that second-quarter profit fell nearly 10%. Increased research and development spending outweighed strong domestic demand for chronic therapies.